Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889406 | 0.85 | MCHR1 (0.73) | ATRMCHR1L3MBTL3HRH3 | |
| SCHEMBL2886450 | 0.84 | MCHR1 (0.58) | ATRMCHR1KMT2AMEN1MAPT | |
| SCHEMBL2890112 | 0.84 | ATR (0.56) | ATRRAB9AMCHR1NPC1POLB | |
| SCHEMBL2885719 | 0.83 | ATR (0.55) | ATRRAB9AMCHR1NPC1KMT2A | |
| SCHEMBL2889859 | 0.83 | IKBKB (0.54) | ATRMCHR1L3MBTL3HRH3PDK2 | |
| SCHEMBL2890336 | 0.83 | ATR (0.55) | ATRMCHR1L3MBTL3HRH3PDK2 | |
| SCHEMBL3858062 | 0.81 | MAOA (0.58) | ATR | |
| SCHEMBL11986399 | 0.80 | NPC1 (0.72) | RAB9ANPC1MAPTL3MBTL3 | |
| SCHEMBL2889902 | 0.80 | ATR (0.61) | ATRMCHR1POLBL3MBTL3HRH3 | |
| SCHEMBL2885755 | 0.79 | HDAC3 (0.57) | ATRMCHR1L3MBTL3DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007136668-A9 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH CORP (US) | 2008-03-27 | — | — | WO | claimed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2027086-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007136668-A9 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH CORP (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | ATR 4689/4885RAB9A 1460/4885MCHR1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.